Asset Details
Do you wish to reserve the book?
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials
Do you wish to request the book?
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials
2014
Overview
Purpose
Palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT
3
RA) with a strong binding affinity and long half-life, has been used in numerous trials for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV). We systematically reviewed the efficacy and safety of palonosetron compared to other 5-HT
3
RAs in CINV prophylaxis.
Methods
A literature search of Ovid MEDLINE, EMBASE, and CENTRAL was conducted to identify randomized controlled trials (RCTs) comparing palonosetron to other 5-HT
3
RAs in CINV prophylaxis. Primary endpoints were the percentage of patients achieving a complete response (CR), complete control (CC), no emesis, no nausea, or taking no rescue medications. Secondary endpoints were the percentage of patients suffering from 5-HT
3
RA-related adverse events.
Results
Sixteen RCTs were identified with 2,896 patients randomized to palonosetron and 3,187 patients randomized to other 5-HT
3
RAs. Palonosetron was consistently statistically superior in CR, CC, no emesis, or no nausea and was sometimes superior in no rescue medication. Subgroup analyses demonstrated similarity in efficacy between highly and moderately emetogenic chemotherapy cohorts. In the acute phase, statistical superiority of palonosetron was found for trials that did not allow dexamethasone; conversely, RCTs that administered dexamethasone to all patients were nonsignificant. Palonosetron was statistically significantly safer in dizziness and mean QTc interval change and similar in constipation, headache, and diarrhea. Clinical superiority of palonosetron was reached in 3 of 19 analyzed efficacy and safety endpoints.
Conclusions
Palonosetron is safer and more efficacious than other 5-HT
3
RAs. Future antiemetic guidelines should discuss the merits of including palonosetron as a first-line treatment.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Analysis
/ Antiemetics - adverse effects
/ Antiemetics - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Cancer
/ Complications and side effects
/ Diarrhea
/ Drugs
/ Efficacy
/ Humans
/ Isoquinolines - adverse effects
/ Isoquinolines - therapeutic use
/ Medicine
/ Nausea
/ Nausea - prevention & control
/ Nursing
/ Oncology
/ Patients
/ Quinuclidines - adverse effects
/ Quinuclidines - therapeutic use
/ Randomized Controlled Trials as Topic
/ Safety
/ Serotonin Antagonists - adverse effects
/ Serotonin Antagonists - therapeutic use
/ Vomiting
